<DOC>
	<DOC>NCT01540604</DOC>
	<brief_summary>This is an investigation of the efficacy and safety of CRD007 in Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy (BMD) and symptomatic carriers.</brief_summary>
	<brief_title>CRD007 for the Treatment of Duchenne Muscular Dystrophy, Becker Muscular Dystrophy and Symptomatic Carriers</brief_title>
	<detailed_description />
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
	<criteria>Documented diagnosis of dystrophinopathy Severe functional impairment</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>DMD</keyword>
	<keyword>BMD</keyword>
	<keyword>symptomatic carriers</keyword>
</DOC>